Skip to main content
Clinical Trials/TCTR20230109003
TCTR20230109003
Completed
Phase 4

The efficacy of intranasal fentanyl as an adjunct for pain management in retinopathy of prematurity screening

Bhumibol Adulyadej Hospital0 sites49 target enrollmentJanuary 9, 2023

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Efficacy of intranasal fentanyl drops as an adjunct for pain management in retinopathy of prematurity screening.
Sponsor
Bhumibol Adulyadej Hospital
Enrollment
49
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 9, 2023
End Date
October 31, 2022
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Neonates considered at risk for retinopathy of prematurity received screening included birth weight \< 1500 g or gestation age \< 30 wks, and retinopathy of prematurity risk even birth weight 1500\-2000 g or gestation age \> 30 wk with post\-menstrual age \> 4 wk and underwent retinopathy of prematurity screening

Exclusion Criteria

  • Neonate who needed invasive mechanical ventilation, were hemodynamically unstable, under sedation, with congenital malformation or neurological dysfunction

Outcomes

Primary Outcomes

Not specified

Similar Trials